Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pan-cancer polygenic risk score associates with cancer susceptibility following kidney transplantation
Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen
Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen
View: Text | PDF
Clinical Research and Public Health Nephrology Oncology

Pan-cancer polygenic risk score associates with cancer susceptibility following kidney transplantation

  • Text
  • PDF
Abstract

BACKGROUND Cancer accounts for over 20% of late posttransplant mortality, yet the contribution of genetic susceptibility to posttransplant cancer risk remains unclear. This study investigates germline genetic risk factors for posttransplant cancer in the Finnish population using data from the FinnGen cohort.METHODS A pan-cancer polygenic risk score (PRS) was constructed using genetic variants identified in UK and US populations to assess the influence of common germline variants on time to first cancer diagnosis in 1,802 Finnish kidney transplant recipients (KTRs), of whom 317 developed posttransplant cancer. The PRS was first validated in the FinnGen non-transplantation cohort and subsequently applied to KTRs, with replication in lung and liver transplant recipients (n = 476). Functional relevance was explored by assessing associations between the PRS and expression levels of 2,923 plasma proteins in the UK Biobank (n = 53,013).RESULTS Compared with a matched non-transplantation cohort (n = 68,294), KTRs exhibited earlier cancer onset. The PRS was significantly associated with time to first cancer diagnosis in the non-transplantation population (HR 1.04, 95% CI 1.038–1.056, P = 3.75 × 10–25). Among KTRs younger than 40 years, higher PRS was associated with earlier cancer onset (HR 1.08, 95% CI 1.01–1.17, P = 0.036), indicating a stronger genetic effect at younger ages. The PRS significantly (Bonferroni < 0.05) altered the regulation of 87 plasma proteins, several of which were known cancer-related markers.CONCLUSION Inherited genetic predisposition, captured by pan-cancer PRS, may contribute to individual susceptibility to cancer after solid organ transplantation, particularly at younger ages.FUNDING State research funding (Helsinki and Uusimaa Health District), the Foundation for Pediatric Research, and the Sigrid Jusèlius Foundation.

Authors

Jarmo Ritari, Kati Hyvärinen, Kirsi Jahnukainen, FinnGen Consortium, Jukka Partanen, Ilkka Helanterä, Timo Jahnukainen

×

Figure 1

Schematic overview of the study.

Options: View larger image (or click on image) Download as PowerPoint
Schematic overview of the study.
(A) Kidney transplantation (KT) patient...
(A) Kidney transplantation (KT) patients receive long-term immunosuppression, which elevates post-KT cancer risk especially in young patients. (B) A pan-cancer polygenic risk score (PRS) is constructed by selecting statistically significant variants from an UK Biobank (UKB) and US Kaiser Permanente (GERA) GWAS meta-analysis (28) and extracting the risk alleles of the selected variants from FinnGen non-transplantation population (n = 496,641). The PRS is a sum of the number of risk variants normalized for cancer type. The pan-cancer PRS is then validated against longitudinal electronic health record data of cancer diagnoses by fitting a multivariate Cox proportional hazards (coxph) survival model for time to first cancer occurrence in FinnGen non-transplantation cohort. (C) The pan-cancer PRS target variants are extracted from the FinnGen KT cohort and the PRS is similarly computed for the KT patients. (D) The PRS in the KT cohort is combined with longitudinal cancer diagnosis data to fit coxph models. The ability of the PRS to stratify KT patients into low- and high-risk groups is evaluated. (E) The effect of the PRS on plasma protein expression levels is measured in the UK Biobank.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts